Global Plasma Derived Medicine Market Size By Type (Albumin, Coagulation Factor), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Plasma Derived Medicine Market was valued at USD 32.4 billion in 2023 and is projected to reach USD 54.7 billion by 2031, growing at a CAGR of 6.9% during the forecast period (2023–2031). Plasma-derived medicines are critical biological therapies used in the treatment of rare, chronic, and life-threatening conditions including immunodeficiencies, hemophilia, and autoimmune disorders. The increasing prevalence of such conditions, coupled with rising demand for plasma donations and advancements in fractionation technology, are significantly driving market growth. Governments and healthcare organizations are also increasingly promoting plasma donation and public awareness initiatives, further bolstering demand.

Drivers

Rising Prevalence of Rare and Chronic Diseases

The growing incidence of immune disorders, bleeding conditions like hemophilia, and liver diseases is a major driver. Plasma-derived products, including immunoglobulins, albumin, and clotting factors, are essential for effective treatment and long-term disease management.

Expansion of Plasma Collection Infrastructure

Countries across North America, Europe, and Asia-Pacific are significantly increasing their investments in plasma collection centers and donor outreach campaigns. Enhanced collection capabilities are improving supply chains and reducing dependence on imports.

Technological Advancements in Plasma Fractionation

Innovations in plasma fractionation techniques are increasing the efficiency of plasma utilization and improving the yield of high-purity therapeutic proteins, thereby supporting broader access to plasma therapies globally.

Restraints

High Production and Regulatory Costs

The plasma derivation process is highly complex, costly, and tightly regulated due to biosafety risks. Meeting these stringent regulatory requirements increases operational costs and can limit the ability of smaller players to compete.

Dependence on Voluntary Plasma Donations

A critical challenge is the market’s dependence on a stable supply of human plasma. Variability in donor turnout and regulatory restrictions on cross-border plasma trade pose ongoing risks to supply continuity.

Opportunity

Growing Penetration in Emerging Economies

The increasing healthcare expenditure and policy support for rare disease treatments in emerging markets such as India, Brazil, and China are opening new avenues for growth. As infrastructure improves, more patients will gain access to these life-saving therapies.

Innovation in Recombinant and Hybrid Therapies

Advances in recombinant DNA technology and hybrid therapeutic approaches are facilitating the development of next-generation plasma-derived medicines that combine high efficacy with fewer side effects, offering new market opportunities.

Market by System Type Insights

By product category, Immunoglobulin dominated the market in 2023, accounting for the largest revenue share due to its broad use in treating immune deficiencies and neurological disorders. It is projected to continue leading, driven by increasing diagnoses of primary immunodeficiency diseases (PIDD). Albumin is expected to show strong growth due to its critical use in liver disease, trauma care, and surgery.

Market by End-use Insights

The Hospitals & Clinics segment represented the largest market share in 2023. This dominance is attributed to the high volume of plasma-derived therapies administered in hospital settings under specialized supervision. The Research & Academic Institutes segment is expected to grow steadily, driven by increased R&D activities and clinical trials focusing on the efficacy of plasma proteins in novel treatments.

Market by Regional Insights

North America led the global plasma derived medicine market in 2023, underpinned by robust plasma collection systems, government funding for rare disease research, and high awareness levels. Asia-Pacific is anticipated to exhibit the fastest growth through 2031, driven by expanding healthcare infrastructure, rising disposable incomes, and supportive governmental policies to increase local plasma sourcing and reduce dependence on imports.

Competitive Scenario

Major players in the Global Plasma Derived Medicine Market include:

CSL Behring

Grifols S.A.

Takeda Pharmaceutical Company Limited

Kedrion S.p.A.

Octapharma AG

Biotest AG

LFB S.A.

ADMA Biologics, Inc.

Sanquin

China Biologic Products Holdings, Inc.

These companies are focused on increasing production capacity, securing regulatory approvals for new indications, and investing in recombinant alternatives to diversify their portfolios.

Scope of Work – Global Plasma Derived Medicine Market

Key Market Developments

2023: CSL Behring inaugurated a new plasma fractionation facility in Germany, boosting its production capacity for immunoglobulin therapies by 30%.

2024: Takeda launched a recombinant albumin therapy in Japan, combining plasma-based expertise with genetic engineering for improved safety.

2025: Grifols expanded its U.S. plasma donation centers by 15%, enhancing supply chain resilience and collection efficiency across North America.

FAQs

What is the current market size of the Global Plasma Derived Medicine Market?

The market was valued at USD 32.4 billion in 2023.

What is the major growth driver of the Global Plasma Derived Medicine Market?

Increasing prevalence of rare and chronic diseases coupled with expanded plasma collection infrastructure.

Which is the largest region during the forecast period in the Global Plasma Derived Medicine Market?

North America remains the largest market, while Asia-Pacific is expected to grow fastest.

Which segment accounted for the largest market share in Global Plasma Derived Medicine Market?

The Immunoglobulin segment led the market in 2023.

Who are the key market players in the Global Plasma Derived Medicine Market?

Key players include CSL Behring, Grifols S.A., Takeda, Kedrion, and Octapharma.

Let me know if you would like a downloadable version or visual chart summary of this report.